文献速递肝病

A-TANGO器官衰竭评分在慢加急性肝衰竭中的开发与验证

Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts.
PubMed 文献 · J Hepatol · 2026-02-21

基于欧美、拉美、印度和中国的前瞻性队列(推导n=3896,验证n=2055和2568),开发并验证A-TANGO器官衰竭评分。该评分修订器官衰竭阈值并新增ACLF 4级,使ACLF诊断率从24%升至36%,净重分类指数提高16%,28天和90天死亡率预测准确性不变。

要点

  • A-TANGO评分修订器官衰竭阈值,新增ACLF 4级以区分CLIF-C OF 3级内的死亡风险差异。
  • 诊断率从24%升至36%,净重分类指数提高16%,28天和90天死亡率预测准确性不变。
  • ACLF-WBC和ACLF-CRP模型与28天和90天死亡率强相关,提升预后性能。

核心结论

  • A-TANGO器官衰竭评分是可重复且全面的ACLF诊断工具,预后性能得以保持,并在大型国际队列中得到验证。

研究设计与样本

  • 回顾性分析前瞻性观察队列,推导队列为欧洲和拉丁美洲三项EF-CLIF联盟研究(CANONIC、PREDICT、ACLARA;n=3896)。
  • 验证队列包括印度Ambi-spective研究(n=2055)和中国CATCH-LIFE研究(n=2568),患者入组于2011至2023年,随访于2023年完成。

主要发现

  • 与CLIF-C OF评分相比,A-TANGO OF评分引入修订的器官衰竭阈值并新增ACLF 4级,以解决CLIF-C OF 3级内死亡率差异大的问题。
  • A-TANGO识别出更多器官衰竭,使ACLF诊断率从24%升至36%,净重分类指数提高16%,同时保持对28天和90天死亡率相似的预测准确性。
  • 两个额外预后模型(A-TANGO ACLF-WBC和A-TANGO ACLF-CRP)与28天和90天死亡率强相关,并改善预后性能,结果在外部验证队列中得到确认。

关键数值与推荐

  • 每个器官使用三个子评分重新定义器官功能障碍和衰竭阈值,子评分3对应≥15%的28天死亡率并定义为器官衰竭。
  • A-TANGO使ACLF诊断率从24%升至36%,净重分类指数提高16%。

临床怎么用

  • A-TANGO OF评分及其相关预后评分(ACLF-WBC和ACLF-CRP)可用于临床实践指导治疗决策。
  • 可作为临床试验中评估新兴疗法的可靠、可测量终点,如ACLF缓解用于治疗反应评估。

局限性

  • 存在数据缺失、队列特异性招募差异和历史分类标准等局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is characterised by multiorgan failure and high short-term mortality in hospitalised patients with acute decompensation of cirrhosis. Although the EASL-CLIF criteria are widely used for diagnosis and prognostication, evolving definitions of organ dysfunction and emerging therapies require updated, tailored criteria to improve diagnostic accuracy, treatment assessment, and applicability in clinical trials. We aimed to develop and validate the A-TANGO organ failure (OF) score to refine ACLF diagnosis and enhance its utility for treatment response evaluation and risk stratification. METHODS: We performed a retrospective analysis of prospective observational cohorts. The derivation cohort comprised three EF-CLIF consortium studies conducted in Europe and Latin America (CANONIC, PREDICT, ACLARA; n = 3,896). Validation cohorts included one study from India (Ambi-spective study n = 2,055) and one from China (CATCH-LIFE; n = 2,568). Patients were enrolled between 2011 and 2023, with follow-up completed in 2023. The primary objective was to redefine thresholds for organ dysfunction and failure using three subscores per organ, with subscore 3 corresponding to ≥15% 28-day mortality and defining organ failure. RESULTS: Compared with the CLIF-C OF score, the A-TANGO OF score introduced revised thresholds for organ failure and added an ACLF grade 4 to address the wide mortality variation within CLIF-C OF grade 3. A-TANGO identified more organ failures, increasing ACLF diagnosis from 24% to 36% and improving the net reclassification index by 16%, while maintaining similar predictive accuracy for 28- and 90-day mortality. Two additional prognostic models (A-TANGO ACLF-WBC and A-TANGO ACLF-CRP) demonstrated strong associations with 28- and 90-day mortality and improved prognostic performance. Findings were confirmed in external validation cohorts. CONCLUSIONS: The A-TANGO OF score is a reproducible and comprehensive tool for ACLF diagnosis with preserved prognostic performance, validated across large international cohorts. It provides a robust framework for clinical trials by enabling more accurate diagnosis, reducing required sample sizes, and offering clinically meaningful endpoints such as ACLF resolution for treatment response assessment. IMPACT AND IMPLICATIONS: The A-TANGO organ failure (OF) score provides a scientifically justified advancement in ACLF research by refining organ-specific dysfunction thresholds and introducing a new grade 4, thereby addressing limitations in current EASL-CLIF criteria and improving identification of high-risk patients. These findings are important for clinicians, researchers, and healthcare systems globally, as they increase detection of organ failure, enhance risk stratification, and enable more accurate prediction of short-term mortality in hospitalized patients with cirrhosis. The A-TANGO OF score and its associated prognostic scores (ACLF-WBC and ACLF-CRP) can be applied in clinical practice to guide treatment decisions, and serve as reliable, measurable endpoints in clinical trials evaluating emerging therapies. Although limitations such as missing data, cohort-specific recruitment differences, and historical classification criteria exist, the consistent and robust performance of the A-TANGO scores across large, multinational cohorts highlights their potential applicability and utility on a global scale.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Engelmann C, Verma N, Qi T, et al. Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts. J Hepatol. 2026. PMID: 41730386. doi:10.1016/j.jhep.2026.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。